Kura Oncology
KURA
141 hedge funds and large institutions have $885M invested in Kura Oncology in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 16 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
20% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 41
3.11% more ownership
Funds ownership: 102.75% → 105.86% (+3.1%)
4% more capital invested
Capital invested by funds: $849M → $885M (+$36.1M)
1% less funds holding
Funds holding: 142 → 141 (-1)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
21% less call options, than puts
Call options by funds: $535K | Put options by funds: $679K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$36.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$6.11M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.08M |
| 5 |
BlackRock
New York
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$18.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.4M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.53M |
| 4 |
Axa
Paris,
France
|
-$3.68M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$2.73M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DFCM
151
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$12K | -970 | Closed |
|
152
Belvedere Trading
Chicago,
Illinois
| – | -$6.27K | -505 | Closed |
|
153
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6K | -469 | Closed |
|
|
TWA
154
TCI Wealth Advisors
Tucson,
Arizona
| – | -$3.95K | -318 | Closed |
|
KURA Hedge Fund Activity: Q1 2023 in Review
141 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2023, worth a combined $885M — up 4.2% from $849M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KURA and 15 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 49 added.
The largest buyer was BVF Inc, adding an estimated $36.6M. The largest seller was Victory Capital Management, exiting entirely with an estimated $18.9M sold.
- 141 institutional investors held Kura Oncology (KURA) as of Q1 2023, down from 142 in Q4 2022.
- Funds reported $885M of Kura Oncology stock for Q1 2023, up 4.2% quarter-over-quarter.
- 15 funds opened new Kura Oncology positions in Q1 2023 and 16 closed out, a net change of -1 holder.
- The largest Kura Oncology buyer in Q1 2023 was BVF Inc, an estimated $36.6M added.
- The largest Kura Oncology seller in Q1 2023 was Victory Capital Management, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2023.